PT  - JOURNAL ARTICLE
AU  - Karaba, Andrew H.
AU  - Zhu, Xianming
AU  - Liang, Tao
AU  - Wang, Kristy H.
AU  - Rittenhouse, Alex G.
AU  - Akinde, Olivia
AU  - Eby, Yolanda
AU  - Ruff, Jessica E.
AU  - Blankson, Joel N.
AU  - Abedon, Aura T.
AU  - Alejo, Jennifer L.
AU  - Cox, Andrea L.
AU  - Bailey, Justin R.
AU  - Thompson, Elizabeth A.
AU  - Klein, Sabra L.
AU  - Warren, Daniel S.
AU  - Garonzik-Wang, Jacqueline M.
AU  - Boyarsky, Brian J.
AU  - Sitaras, Ioannis
AU  - Pekosz, Andrew
AU  - Segev, Dorry L.
AU  - Tobian, Aaron A.R.
AU  - Werbel, William A.
TI  - A Third Dose of SARS-CoV-2 Vaccine Increases Neutralizing Antibodies Against Variants of Concern in Solid Organ Transplant Recipients
AID  - 10.1101/2021.08.11.21261914
DP  - 2021 Jan 01
TA  - medRxiv
PG  - 2021.08.11.21261914
4099  - http://medrxiv.org/content/early/2021/10/13/2021.08.11.21261914.short
4100  - http://medrxiv.org/content/early/2021/10/13/2021.08.11.21261914.full
AB  - Vaccine-induced SARS-CoV-2 antibody responses are attenuated in solid organ transplant recipients (SOTRs) and breakthrough infections are more common. Additional SARS-CoV-2 vaccine doses increase anti-spike IgG in some SOTRs, but it is uncertain whether neutralization of variants of concern (VOCs) is enhanced. We tested 47 SOTRs for clinical and research anti-spike IgG, pseudoneutralization (ACE2 blocking), and live-virus neutralization (nAb) against VOCs before and after a third SARS-CoV-2 vaccine dose (70% mRNA, 30% Ad26.COV2.S) with comparison to 15 healthy controls after two mRNA vaccine doses. We used correlation analysis to compare anti-spike IgG assays and focused on thresholds associated with neutralizing activity. A third SARS-CoV-2 vaccine dose increased median anti-spike (1.6-fold) and receptor-binding domain (1.5-fold) IgG, as well as pseudoneutralization against VOCs (2.5-fold versus Delta). However, IgG and neutralization activity were significantly lower than healthy controls (p<0.001); 32% of SOTRs had zero detectable nAb against Delta after third vaccination. Correlation with nAb was seen at anti-spike IgG >4 AU on the clinical assay and >10^4 AU on the research assay. These findings highlight benefits of a third vaccine dose for some SOTRs and the need for alternative strategies to improve protection in a significant subset of this population.Competing Interest StatementDLS has the following financial disclosures: consulting and speaking honoraria from Sanofi, Novartis, CSL Behring, Jazz Pharmaceuticals, Veloxis, Mallinckrodt, Thermo Fisher Scientific. None of the other authors have any relevant competing interests.Funding StatementThis work was supported by the Ben-Dov family, the Johns Hopkins COVID-19 Vaccine-related Research Fund, the National Cancer Institute (U54CA260491), grants 5T32DK007713 (JLA), F32DK124941 (BJB), and K23DK115908 (JMGW) from the National Institute of Diabetes and Digestive and Kidney Diseases, and grants K24AI144954 (DLS), K08AI156021 (AHK), and R01AI120938S1 (AART) from the National Institute of Allergy and Infectious Disease. Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:SOTR participants were enrolled in a national prospective, observational cohort: COVID-19 Antibody Testing of Recipients of Solid Organ Transplants and Patients with Chronic Diseases, Johns Hopkins IRB00248540. Healthy control participants were enrolled under Johns Hopkins IRB00027183.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).Yes I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesReasonable requests to the corresponding author for de-identified data will be granted.Anti-NAnti-nucleocapsid antibodyAnti-RBDAnti-Receptor Binding Domain antibodyAnti-SAnti-Spike antibodyAUArbitrary UnitAUCArea Under the CurveCFRCase Fatality RateCMComplete MediaELISAenzyme-linked immunosorbent assayHCHealthy ControlIMInfection MediaMSDMeso Scale DiagnosticsnAbNeutralizing antibodyNT5050% Neutralization TiterODOptical DensitySOTRSolid Organ Transplant RecipientTCID5050% Tissue Culture Infectious DoseVOCVariant of Concern